Patents by Inventor Gary Mitchell

Gary Mitchell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12139499
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted benzothiazole compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: November 12, 2024
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Nanjing Zhang, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Guangming Chen, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Nadiya Sydorenko, Anthony Turpoff, Matthew G. Woll, Wuming Yan
  • Publication number: 20240336613
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: July 29, 2022
    Publication date: October 10, 2024
    Inventors: Suresh BABU, Rauful ALAM, Anuradha BHATTACHARYYA, Guangming CHEN, Matthew S. EASTWOOD, Seyedmorteza HOSSEYNI, Yao JIANG, Gary Mitchell KARP, Young-Choon MOON, Jana NARASIMHAN, Hongyu REN, Nadiya SYDORENKO, Matthew G. WOLL, Nanjing ZHANG
  • Patent number: 12034800
    Abstract: The invention is that of systems and methods for controllerless and distributed network connections to servers on a network by remote clients seeking their services. The invention comprises a central database where servers within a server group identified by a group name may post unique identifiers (UIDs) for retrieval and reposting by group clients configured with the group name, which may query the central database for server connection information such as uptime, downtime, and congestion in order to select a server for a preferential connection based on an overall posture as determined by the group client. In some embodiments, one server of the group is a “dummy server” that may aggregate and selectively transmit server information from other servers in the group, or other devices, and post it to the central database. The methods described herein eliminate a separate controller and thereby a single point of failure (SPOF).
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: July 9, 2024
    Assignee: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Patent number: 12034799
    Abstract: The invention is that of systems and methods for controllerless and distributed network connections to servers on a network by remote clients seeking their services. The invention comprises a central database where servers within a server group identified by a group name may post unique identifiers (UIDs) for retrieval by group clients configured with the group name, which may query the central database for server connection information such as uptime, downtime, and congestion in order to select a server for a preferential connection based on an overall availability profile as determined by the group client. In some embodiments, one server of the group is a “dummy server” that may aggregate and selectively transmit server information from other servers in the group, or other devices, and posts it to the central database for client access. The methods described herein eliminate a separate controller and thereby a single point of failure (SPOF).
    Type: Grant
    Filed: September 12, 2022
    Date of Patent: July 9, 2024
    Assignee: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20240132509
    Abstract: Disclosed are quinoline and quinazoline compounds which modulate the activity of the gated ion channels. Compounds that modulate these gated ion channels are useful in the treatment of diseases and disorders related to pain, inflammation, the neurological system, the gastrointestinal system and genitourinary system. Preferred compounds include quinoline or quinazoline derivatives substituted at the 4-position via N(H), C(O) or O moieties.
    Type: Application
    Filed: November 13, 2023
    Publication date: April 25, 2024
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
  • Publication number: 20240067646
    Abstract: Provided herein are compounds of Formula (I): and forms thereof, including compositions thereof and uses therewith for treating spinal muscular atrophy.
    Type: Application
    Filed: July 26, 2023
    Publication date: February 29, 2024
    Inventors: Hongyan QI, Soongyu CHOI, Amal DAKKA, Gary Mitchell KARP, Jana NARASIMHAN, Nikolai NARYSHKIN, Anthony A. TURPOFF, Marla L. WEETALL, Ellen WELCH, Matthew G. WOLL, Tianle YANG, Nanjing ZHANG, Xiaoyan ZHANG, Xin ZHAO, Luke GREEN, Emmanuel PINARD, Hasane RATNI
  • Patent number: 11858941
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heterocyclic and heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: January 2, 2024
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Michael A. Arnold, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Aleksey I. Gerasyuto, Gary Mitchell Karp, Andrew J. Kassick, Anthony R. Mazzotti, Young-Choon Moon, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Matthew G. Woll, Wuming Yan, Nanjing Zhang
  • Patent number: 11799690
    Abstract: The invention is that of systems and methods for communications between one or more networks and subsequently network devices configured with a networking application for processing network based communications when the devices are on different logical and physical networks. The methods herein involve translation of remote IP addresses of LAN devices to addresses comprising headend network prefixes, to allow for LAN extension of remote to headend networks and communications between devices on the disparate networks. Data packets from a remote LAN interface are transferred to an outbound interface once translated, then forwarded via a formed bridged tunnel link to a headend network device. A server comprising a local LAN and outbound interface is further configured with a NAT module for IP address translation and an optional security module for additional authenticity verification of remote devices attempting to penetrate the headend network.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: October 24, 2023
    Assignee: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20230331725
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: June 16, 2023
    Publication date: October 19, 2023
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
  • Patent number: 11780839
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted monocyclic heteroaryl compounds of Formula (I) or Formula (II), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: March 27, 2019
    Date of Patent: October 10, 2023
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Nadiya Sydorenko, Md Rauful Alam, Lukiana Amedzo, Suresh Babu, Ramil Y. Baiazitov, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Nathaniel T. Kenton, Anthony R. Mazzotti, Young-Choon Moon, Nicholas W. Mszar, Jana Narasimhan, Sudipta Pal, Jigar S. Patel, Anthony Turpoff, Matthew G. Woll, Zhenrong Xu, Nanjing Zhang
  • Patent number: 11753407
    Abstract: Provided herein are compounds of Formula (I): and forms thereof, wherein w1, w2, w3, w4, w5, w6 and w7 are as defined herein, including compositions thereof and uses therewith for treating spinal muscular atrophy.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: September 12, 2023
    Assignees: PTC Therapeutics, Inc., F. Hoffmann-La Roche AG
    Inventors: Hongyan Qi, Soongyu Choi, Amal Dakka, Gary Mitchell Karp, Jana Narasimhan, Nikolai Naryshkin, Anthony A. Yurpoff, Marla L. Weetall, Ellen Welch, Matthew G. Woll, Tianle Yang, Nanjing Zhang, Xiaoyan Zhang, Xin Zhao, Luke Green, Emmanuel Pinard, Hasane Ratni
  • Publication number: 20230234942
    Abstract: The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: April 8, 2021
    Publication date: July 27, 2023
    Inventors: Nadiya Sydorenko, Rauful Alam, Suresh Babu, Anuradha Bhattacharyya, Guangming Chen, Matteo Chierchia, Gary Mitchell Karp, Tom Tuan Luong, Anthony R. Mazzotti, Young-Choon Moon, Nicholas Walter Mszar, Jana Narasimhan, Jigar S. Patel, Hongyu Ren, Gang Wang, Matthew G. Woll, Nanjing Zhang, Xiaoyan Zhang
  • Patent number: 11685746
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), Formula (II), Formula (III), or Formula (IV), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: June 27, 2023
    Assignee: PTC Therapeutics, Inc.
    Inventors: Guangming Chen, Anuradha Bhattacharyya, Yao Jiang, Gary Mitchell Karp, Jana Narasimhan, Anthony Turpoff, Nanjing Zhang
  • Publication number: 20230057568
    Abstract: The present description relates to compounds useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno [3,2-d]pyrimidine compounds, forms, and pharmaceutical compositions thereof and methods of use for treating or ameliorating familial dysautonomia.
    Type: Application
    Filed: December 7, 2020
    Publication date: February 23, 2023
    Applicant: PTC THERAPEUTICS, INC.
    Inventors: Nanjing ZHANG, Michael A. ARNOLD, Amal DAKKA, Gary Mitchell KARP, Tom Tuan LUONG, Christie MORRILL, Jana NARASIMHAN, Nikolai A. NARYSHKIN, Anthony TURPOFF, Jiashi WANG, Xiaoyan ZHANG
  • Patent number: 11477276
    Abstract: The invention is that of systems and methods for controllerless and distributed network connections to servers on a network by remote clients seeking their services. The invention comprises a server database where servers within a server group identified by a groupname may post unique identifiers (UIDs) for retrieval by group clients configured with the groupname, which may query the server database for server connection information such as uptime, downtime, and congestion in order to select a server for a preferential connection based on an overall availability profile as determined by the group client. The methods described herein eliminate a separate controller and thereby eliminate the single point of failure (SPOF) represented by connection controllers and load balancers in a network as are common in the current state of the art.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 18, 2022
    Assignee: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20220278960
    Abstract: The invention is that of systems and methods to reduce or eliminate network resource exposure to unauthorized network users. The methods described herein are designed to only permit authenticated remote network device access to central network services based on the content of requests from remote network devices seeking access. A system as described herein is configured with conditional access grantor and request modules located on central and remote networks, respectively. A conditional access grantor module dynamically configures a central network firewall or equivalent to permit or deny access from the specific devices on the remote network. A database is provided for storing of remote device details or parameters supplied by the grantor module and required for connection thereby to the central network.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 1, 2022
    Applicant: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20220272147
    Abstract: The invention is that of systems and methods for controllerless and distributed network connections to servers on a network by remote clients seeking their services. The invention comprises a server database where servers within a server group identified by a groupname may post unique identifiers (UIDs) for retrieval by group clients configured with the groupname, which may query the server database for server connection information such as uptime, downtime, and congestion in order to select a server for a preferential connection based on an overall availability profile as determined by the group client. The methods described herein eliminate a separate controller and thereby eliminate the single point of failure (SPOF) represented by connection controllers and load balancers in a network as are common in the current state of the art.
    Type: Application
    Filed: February 24, 2021
    Publication date: August 25, 2022
    Applicant: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20220255930
    Abstract: The invention is that of systems and methods for communications between one or more networks and subsequently network devices configured with a networking application for processing network based communications when the devices are on different logical and physical networks. The methods herein involve translation of remote IP addresses of LAN devices to addresses comprising headend network prefixes, to allow for LAN extension of remote to headend networks and communications between devices on the disparate networks. Data packets from a remote LAN interface are transferred to an outbound interface once translated, then forwarded via a formed bridged tunnel link to a headend network device. A server comprising a local LAN and outbound interface is further configured with a NAT module for IP address translation and an optional security module for additional authenticity verification of remote devices attempting to penetrate the headend network.
    Type: Application
    Filed: February 10, 2021
    Publication date: August 11, 2022
    Applicant: IP Technology Labs, LLC
    Inventors: Gary Mitchell, Scott Whittle, Kurt Quasebarth
  • Publication number: 20220251098
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Application
    Filed: April 18, 2022
    Publication date: August 11, 2022
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu
  • Patent number: 11407753
    Abstract: The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. In particular, the present description relates to substituted bicyclic heteroaryl compounds of Formula (I), forms and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
    Type: Grant
    Filed: June 5, 2018
    Date of Patent: August 9, 2022
    Assignee: PTC THERAPEUTICS, INC.
    Inventors: Matthew G. Woll, Lukiana Amedzo, Suresh Babu, Scott J. Barraza, Anuradha Bhattacharyya, Gary Mitchell Karp, Anthony R. Mazzotti, Jana Narasimhan, Jigar Patel, Anthony Turpoff, Zhenrong Xu